

# Classifying the Progression of Ductal Carcinoma from Single-Cell Sampled Data via Integer Linear Programming: A Case Study

Daniele Catanzaro, Stanley E. Shackney, Alejandro A. Schäffer, and Russell Schwartz

**Abstract**—Ductal Carcinoma In Situ (DCIS) is a precursor lesion of Invasive Ductal Carcinoma (IDC) of the breast. Investigating its temporal progression could provide fundamental new insights for the development of better diagnostic tools to predict which cases of DCIS will progress to IDC. We investigate the problem of reconstructing a plausible progression from single-cell sampled data of an individual with synchronous DCIS and IDC. Specifically, by using a number of assumptions derived from the observation of cellular atypia occurring in IDC, we design a possible predictive model using integer linear programming (ILP). Computational experiments carried out on a preexisting data set of 13 patients with simultaneous DCIS and IDC show that the corresponding predicted progression models are classifiable into categories having specific evolutionary characteristics. The approach provides new insights into mechanisms of clonal progression in breast cancers and helps illustrate the power of the ILP approach for similar problems in reconstructing tumor evolution scenarios under complex sets of constraints.

**Index Terms**—Tumor profiling, single-cell sequencing, ductal carcinoma of the breast, phylogeny estimation, parsimony criterion, computational biology, distance methods, network design, combinatorial optimization, mixed integer linear programming

## 1 INTRODUCTION

DUCTAL Carcinoma In Situ (DCIS) is considered a precursor lesion for invasive breast cancer and is found synchronously in approximately 45 percent of patients affected by Invasive Ductal Carcinoma (IDC) [1]. Specifically, DCIS is the last step in a continuum of non-invasive stages of increased cellular atypia, which are believed to develop from flat epithelial atypia and atypical ductal hyperplasia [2]. Incidences of DCIS and IDC were estimated at 35 and 155 per 100,000 women in the United States, respectively some years ago [3], [4]. The incidences of DCIS and early-stage IDC are expected to increase due to improvements in accuracy of mammography and its increased usage [5]. Investigating the temporal progression of solid tumors could provide fundamental new insights for the development of more effective diagnoses and treatments. Hence, increasing research efforts have been devoted to this topic in recent years [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. The topic has been reviewed in [17], [18].

Several studies have been performed on the dynamics of genomic alterations during the evolution of breast cancer using comparative genomic hybridization (CGH) data [19], mutation data [20], [21], [22], or fluorescence in situ hybridization (FISH) data [7], [11], [23], [24]. In this case study, we focus on reanalyzing the data collected on DCIS and IDC in [23]. Specifically, the authors carried out a single-cell FISH analysis [7], [20], [21], [25] on 13 patients with synchronous DCIS and IDC of the breast. Heselmeyer-Haddad and colleagues observed both an enormous intercellular heterogeneity in DCIS and IDC (although lower in DCIS with respect to IDC) and signal patterns consistent with a non-random distribution of genomic imbalances. The presence of recurrent patterns of genomic imbalances in the evolution from DCIS to IDC led the authors to suspect that similar sequences of genetic events might underlie progression across the patient cohort, enabling a classification. However, the partial classification proposed in [23] is based on static analysis of the single-cell data, not a model of progressing genetic changes.

Recent studies in various tumor types have shown extensive intra-tumor heterogeneity [26] either when the molecular data are point mutations [27], [28] or when the data are gene copy numbers measured by FISH [29], [30], as we use in this study. Therefore, modeling tumor progression based on single-cell data, as we do here, should yield more accurate models than analyses based on tumor-wide data on copy number or mutations [31]. Subsequent phylogenetic analyses [15], [16] of the data of [23] provided a proof of principle that one can reconstruct models of progression for DCIS and IDC data capable of identifying distinguishing features of amplification and loss of specific driver genes. Such work is, however, limited by the computational difficulty of accurately fitting phylogenetic trees to tumor data,

- D. Catanzaro is with the Louvain School of Management and the Center for Operations Research and Econometrics (CORE), Université Catholique de Louvain (UCL), Chaussée de Binche, 1517000, Mons, Belgium. E-mail: daniele.catanzaro@uclouvain.be.
- S.E. Shackney was with the Departments of Human Oncology and Human Genetics, Drexel University School of Medicine, Pittsburgh, PA 15243.
- A.A. Schäffer is with the Computational Biology Branch of NCBI, NIH, Bethesda, MD 20894. E-mail: aschaffe@helix.nih.gov.
- R. Schwartz is with the Department of Biological Sciences and the Computational Biology Department, Carnegie Mellon University, Pittsburgh, PA 15213. E-mail: russells@andrew.cmu.edu.

Manuscript received 21 Jan. 2015; revised 5 May 2015; accepted 26 Aug. 2015. Date of publication 4 Sept. 2015; date of current version 4 Aug. 2016. For information on obtaining reprints of this article, please send e-mail to: reprints@ieee.org, and reference the Digital Object Identifier below. Digital Object Identifier no. 10.1109/TCBB.2015.2476808

particularly with regard to extending algorithmic theory of phylogenetics to cover realistic models of genomic copy number evolution. Further, none of the existing methods for single-tumor phylogenetics, to our knowledge, is able to explicitly consider models of progression, such as DCIS/IDC data or explicit time-series samples, that would have a clinically defined sequence of progression among samples.

Using the data of [23], in this article, we address the problem of modeling and classifying progression of ductal carcinoma by single-cell phylogenetic analysis of tumors from a population of affected individuals. By making use of assumptions derived from the observation of cellular atypia occurring in ductal carcinoma, we first design a possible parsimony-based predictive model able to reconstruct a plausible progression of the carcinoma from single-cell samples of a patient. The modeling uses integer linear programming (ILP) to fit the single-cell data to a set of constraints that are intended to capture a model of our prior biological knowledge of plausible pathways of progression. The values of some variables in an optimal solution of the ILP are interpreted as a structured model of progression. The use of mathematical programming to model tumor progression from molecular data was suggested by Farahani and Lagergren [32]. Mathematical programming and optimization have been used in a previous study on the relationship between DCIS and IDC [33], but that study was based on clinical characteristics of the patients without molecular data. Interestingly, a follow-up study on the same data suggested that mixture models allowing for two different types of clinical progression fit the data much better than any single model [34]. Mixture modeling has also been used effectively to infer tumor progression pathways from CGH data [35], [36]. In that same spirit, our computational experiments using FISH data show that the corresponding predicted progressions are non-random and classifiable into categories having specific evolutionary characteristics.

## 2 PROFILING THE PROGRESSION OF DUCTAL CARCINOMA FROM SINGLE-CELL SAMPLED DATA

In this section, we briefly describe the data collected in [23] and introduce a number of biological and evolutionary assumptions that will prove useful to approximate progression of the tumor pathology considered here.

### 2.1 Sample Data

The literature on tumorigenesis shows that progression of a tumor proceeds over time by increasing atypia from a normal cell [10], [11]. In ductal carcinoma, such atypia may affect, among other things, the number of copies of chromosomal segments and the number of genes in those segments (see [23]). Hence, the variation of the copy number of a (set of) gene(s) can be used as a measure of progression of a cancer cell with respect to the healthy cells.

The data collected in [23] have been extracted from a cohort of 13 patients affected with synchronous DCIS and IDC and include copy numbers of five oncogenes: *COX2* (cyclooxygenase 2, located on 1q31.1), *MYC* (c-MYC, located on 8q24.21), *HER2* (human epidermal growth factor

TABLE 1  
Characteristics of the Analyzed Datasets

Dataset	Number of DCIS taxa	Number of IDC taxa	Overall number of distinct taxa
DAT01	123	119	207
DAT02	35	76	100
DAT03	79	69	115
DAT04	102	120	181
DAT05	58	57	77
DAT06	33	93	118
DAT07	84	76	128
DAT08	92	69	109
DAT09	71	69	137
DAT10	126	102	138
DAT11	77	99	146
DAT12	92	124	172
DAT13	57	97	114

receptor 2, located on 17q12), *CCND1* (cyclin D1, located on 11q13.3) and *ZNF217* (zinc finger protein 217, located on 20q13.2) and three tumor suppressor genes namely, *DBC2* (deleted in breast cancer, located on 8p21.3), *CDH1* (cadherin1, also known as epithelial cadherin, located on 16q22.1) and *TP53* (tumor protein p53, located on 17p13.1). Numerous studies have shown that the considered oncogenes are preferentially gained in tumor pathologies of the breast and that the tumor suppressor genes are preferentially lost in these pathologies [23]. In particular, losses of *TP53* mechanistically promote instability in the genome (see [37]), and hence variations of the copy number of *TP53* deserve special attention. Given a population of individuals affected by DCIS and IDC, we assume that for each individual, data on DCIS and IDC single-cell samples (or *taxa*) are available. Here, we refer to the paired samples for one patient as a *dataset* and the datasets are numbered DAT1 through DAT13. For each cell of the either sample in a dataset, the ordered list of copy numbers of the eight genes is called a *taxon*. We encode each taxon as a sequence of eight numbers each of which represents the number of copies of one gene. For example, the sequence (2.2.4.2.1 – 1.2.3) describes a taxon having (in the following order): two copies of *COX2*, two copies of *MYC*, four copies of *HER2*, two copies of *CCND1*, one copy of *ZNF217*, one copy of *DBC2*, two copies of *CDH1*, and three copies of *TP53*, respectively. By convention, we use the dot to separate the copies of different genes in a given taxon and the dash to separate oncogenes from tumor suppressor genes. Different cells may have the same copy number taxon; the multiplicity of each taxon is part of the data, but not used in our modeling. The number of distinct taxa, ignoring multiplicity, in a sample ranges from 35 to 126 for these data (see Table 1).

### 2.2 Biological Assumptions

Human populations show an extensive polymorphism in the number of copies of some chromosomal segments and genes, called *Copy Number Variants* (CNVs), even among twins [38], but such benign CNVs have not been reported for the eight genes studied here. All eight genes are on autosomes, not the X chromosome. Therefore, it usually holds that healthy cells carry two copies of each gene, i.e., healthy cells can be represented by the taxon (2.2.2.2.2 – 2.2.2) [23].

Hence, we consider the all-2 taxon as the origin of progression of ductal carcinoma in each patient.

During progression of the carcinoma, the copy number of a gene can potentially increase indefinitely or decrease to zero. Once a gene is lost entirely in a given taxon  $t$ , it is plausible to believe that such a gene cannot be regained in a subsequent descendant of  $t$ . Hence, we exclude the possibility that a generic taxon having zero copies of a specific gene, e.g.,  $\langle 2.2.4.2.1 - 0.2.3 \rangle$ , could be considered as the ancestor of any other taxon in the same dataset having a strictly positive number of copies of that gene, e.g.,  $\langle 2.2.4.2.1 - k.2.3 \rangle$ , with  $k > 0$ . We refer to this assumption as the *ex nihilo nihil assumption*.

Similarly to [11], we also assume that: (i) invasive tumors still contain cancer cells from earlier progression steps even if they have not been sampled; (ii) the rate of cell proliferation and death is not significantly different among taxa; and (iii) the cells sampled in each dataset are a reasonable representation of the whole tumor. Moreover, we also assume that: (iv) the copy number of a gene can freely increase or decrease (provided that it remains strictly positive) along a given pathway; and (v) the temporal progression should be respected, i.e., that DCIS taxa should temporally precede IDC taxa (although this assumption is relaxed later).

We further consider some additional assumptions to specifically reflect a model of the effects of *TP53* loss. In particular, we assume that (vi) an increment of the number of copies of *TP53* in a given taxon may potentially cause a *Doubling-Loss Event* (DLE) in its immediate descendant, i.e., a doubling of the number of copies of (all or part of) the genes in the taxon followed by a possible loss of copies of one or more genes (see [23]). Moreover, we assume that in absence of an alteration of the copy number of *TP53* it is unlikely: (vii) to have more than three genes whose corresponding copy numbers double in a generation or (viii) to gain more than 3 copies of a gene in a generation. Finally, we assume that (ix) in case of a decrement of the copy number of *TP53* it is unlikely that the immediate descendant gains more than three copies of a gene. It is worth noting that these assumptions may not be strictly conserved on real data because *TP53* dysfunctions, or functionally equivalent abnormalities, can occur by means of a variety of mechanisms beyond *TP53* copy number variation and that might not be visible in FISH data. Nonetheless, we include these additional assumptions in part to illustrate the kind of complex constraints for which the ILP approach is especially well suited.

### 2.3 The Estimation Criterion

The assumptions described above provide a list of the characteristics that we will assume should or could be included in any plausible prediction of progression of ductal carcinoma affecting a given patient. However, it is worth noting that these assumptions provide neither a criterion to predict progression itself nor a criterion to select a prediction from among plausible alternatives. Hence, in order to predict the progression of ductal carcinoma in a patient, two problems to be solved include identifying both a construction criterion and a selection criterion. As ductal carcinoma is a somatic evolutionary process, a possible approach to identify both criteria consists of using classical evolutionary theory [39].

Specifically, provided a measure of the dissimilarity among taxa, the theory assumes that one taxon evolves from another by means of “small progressive changes,” mainly because the selective forces acting on that taxon may not be constant throughout its evolution [40], [41]. Over time, a collection of small changes will not generally provide the smallest accumulated change. However, if the changes are sufficiently small and the time scales over which taxa would be expected to have evolved are sufficiently short, the process of approximating small changes with the smallest change can properly fit the corresponding evolutionary process [39]. This criterion, known in the literature as the *parsimony criterion* [39], suggests both a method to predict progression itself (e.g., by joining similar taxa at each step of the progression from the healthy taxon) and a criterion to select a prediction from among plausible alternatives (e.g., by choosing the one that globally minimizes the dissimilarity among all taxa in the dataset, [42]). The large number of taxa per patient in the available FISH datasets and relatively short time scales over which they would be expected to have evolved (months to years) both support the use of parsimony over more sophisticated likelihood models for this kind of data. The small number of markers typically available and the frequent presence of ancestral cell states within the observed data also make this problem poorly suited for fast distance-based phylogeny methods, such as neighbor-joining or UPGMA [43], and similar hierarchical clustering algorithms. However, the use of the parsimony criterion involves solving a particular network design problem whose optimal solution has to satisfy the assumptions described in Section 2.2. In the next section we shall formalize this problem and develop a possible mathematical programming approach to solve it exactly.

## 3 MODELING THE PARSIMONY CRITERION

The use of the parsimony criterion involves, as a first task, the identification of a measure of dissimilarity between taxa. As a generic taxon in a given dataset can be seen as a point in an eight-dimensional space, a possible measure of the dissimilarity between a generic pair of taxa in the dataset can be obtained by identifying a specific norm function able to reflect appropriately some or all of the assumptions listed Section 2.2. Before investigating this issue, we introduce some notation that will prove useful throughout the article.

### 3.1 Notation

We define  $D$  to be the set of sample data from a specific patient,  $\mathcal{G}$  to be the set of the eight genes sorted according to the order described in Section 2.1, and  $g$  to be a generic gene in  $\mathcal{G}$ . Given a taxon  $t_i \in D$ , we define  $t_i^g$  to be the copy number of the  $g$ th gene in  $t_i$ . For example, if  $t_i = \langle 4.3.4.5.1 - 4.4.3 \rangle$  then  $t_i^{HER2} = 4$ . We define  $\mathcal{O}$  and  $\mathcal{S}$  to be the sets of the oncogenes and the tumor suppressor genes in  $\mathcal{G}$ , respectively. Finally, we define *DCIS* and *IDC* to be the subsets of DCIS and IDC taxa in  $D$ , respectively, and  $ISI = DCIS \cap IDC$ . We assume only distinct taxa in the DCIS and the IDC individually, but the same taxon may occur in both. We assume that  $D$  always contains the healthy taxon, defined

by having two (diploid) copy number for all genes. If this healthy taxon is missing from the input data, we add it in  $D$ . Moreover, we sort taxa in  $D$  in such a way that (i) the healthy taxon is the first taxon in  $D$ ; (ii) taxa in  $DCIS$  and  $IDC$  follow a tree-structured partial order; (iii) taxa in  $DCIS$  are located after the healthy taxon; and (iv) a taxon that occurs only in  $IDC$  cannot precede a taxon that occurs only in  $DCIS$ . Given a pair of distinct taxa  $t_i, t_j \in D$ ,  $i < j$ , we define  $\omega_{ij}^g = |t_i^g - t_j^g|$ , for all  $g \in \mathcal{G}$ . We define  $\eta_{\mathcal{O}}$  as the number of oncogenes whose counts have doubled during the transition from taxon  $t_i$  to taxon  $t_j$ . Moreover, for a fixed dataset  $D$  we define the following sets:

$$R_1 = \{(t_i, t_j) : \exists g \in \mathcal{G} : t_i^g = 0 \wedge t_j^g > 0\} \quad (1)$$

$$R_2 = \{(t_i, t_j) : t_i \in IDC, t_j \in DCIS\} \quad (2)$$

$$R_3 = \{(t_i, t_j) : t_i^{TP53} = t_j^{TP53}, \eta_{\mathcal{O}} \geq 3\} \quad (3)$$

$$R_4 = \{(t_i, t_j) : t_i^{TP53} = t_j^{TP53} \wedge \exists g \in \mathcal{G} : \omega_{ij}^g \geq 3\} \quad (4)$$

$$R_5 = \{(t_i, t_j) : t_i^{TP53} > t_j^{TP53} \wedge \exists g \in \mathcal{O} : t_i^g \geq 3t_j^g\}. \quad (5)$$

The set  $R_1$  denotes the set of pairs of taxa in  $D$  violating the *ex nihilo nihil* assumption. The set  $R_2$  denotes the set of pairs of taxa in  $D$  violating the temporal progression assumption (v) in a direct transition from ancestor to descendent. The sets  $R_3$ ,  $R_4$  and  $R_5$  denote the sets of pairs of taxa in  $D$  violating the assumptions (vii), (viii) and (ix), respectively.

### 3.2 Measuring the Dissimilarity among Taxa

As a generic taxon in the FISH dataset  $D$  can be encoded as an eight-dimensional vector, a natural choice to measure the dissimilarity between taxa  $t_i, t_j \in D$  is the  $L_1$  distance [15], defined as:

$$d_1(t_i, t_j) = \|t_i - t_j\|_1 = \sum_{g \in \mathcal{G}} \omega_{ij}^g. \quad (6)$$

However, this measure is characterized by a major drawback: it does not take into account the evolutionary process related to the transition from  $t_i$  to  $t_j$ . As a result, the same distance can be assigned to different evolutionary processes, which in turn can be interpreted as equiprobable events, even if they are not in reality. For example, consider the following list of three taxa:  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$ ,  $t_2 = \langle 1.1.1.1.2 - 2.2.2 \rangle$  and  $t_3 = \langle 2.2.2.2.6 - 2.2.2 \rangle$ . If we use Equation (6) to compute the dissimilarity between the healthy cell and the remaining two taxa we get  $d(t_1, t_2) = d(t_1, t_3) = 4$ . This fact means that, if the transition from  $t_1$  to  $t_2$  and from  $t_1$  to  $t_3$  happened in just one generation, the process of losing one copy in genes *COX2*, *MYC*, *HER2* and *CCND1* during evolution from  $t_1$  to  $t_2$  would be an event as likely as gaining four copies of *ZNF217* during evolution from  $t_1$  to  $t_3$ . As our classification attempt is based on the parsimony criterion, we assume that the transition from  $t_1$  to

$t_3$  is more likely than the transition from  $t_1$  to  $t_2$ , because it involves a change in a smaller number of genes. One approach to account for this fact consists of modifying Equation (6) as follows:

$$d_2(t_i, t_j) = d_1(t_i, t_j) + c_1(|\mathcal{G}| - \mu_{ij}), \quad (7)$$

where  $\mu_{ij}$  is the number of equal entries (copy numbers) in taxa  $t_i, t_j \in D$  and  $c_1$  is a positive constant used to weight added  $\mu_{ij}$ . For example, if we set  $c_1 = 1/8$  then we get  $\mu_{12} = 5$ ,  $\mu_{13} = 7$ ,  $d(t_1, t_2) = 4.375$  and  $d(t_1, t_3) = 4.125$ . Hence, the transition from  $t_1$  to  $t_3$  becomes more likely than the transition from  $t_1$  to  $t_2$ . It is worth noting that the addend  $c_1(|\mathcal{G}| - \mu_{ij})$  represents the Hamming distance between vectors  $t_i$  and  $t_j$ , weighted by the positive constant  $c_1$ . We denote this addend as  $H(t_i, t_j)$ .

The following proposition holds:

**Proposition 1.** *The function  $d_2(\cdot, \cdot)$  induces a metric space in  $D$ .*

**Proof.** If  $d_2(\cdot, \cdot)$  is a metric then it has to satisfy the following properties:

- (1)  $d_2(t_i, t_j) \geq 0$  (non-negativity);
- (2)  $d_2(t_i, t_j) = 0$  iff  $t_i = t_j$  (coincidence axiom);
- (3)  $d_2(t_i, t_j) = d_2(t_j, t_i)$  (symmetry);
- (4)  $d_2(t_i, t_z) \leq d_2(t_i, t_j) + d_2(t_j, t_z)$  (triangle inequality).

It is easy to see that  $d_2(\cdot, \cdot)$  satisfies the first three properties. To show that  $d_2(\cdot, \cdot)$  also satisfies the triangle inequality, observe that the following inequality holds:

$$\begin{aligned} d_2(t_i, t_z) &= \|t_i - t_z\|_1 + H(t_i, t_z) \\ &\leq \|t_i - t_j\|_1 + H(t_i, t_j) + \|t_j - t_z\|_1 + H(t_j, t_z). \end{aligned} \quad (8)$$

Inequality (8) can be seen as the convex combination (with multipliers equal to 1) of the following two inequalities:

$$\|t_i - t_z\|_1 \leq \|t_i - t_j\|_1 + \|t_j - t_z\|_1 \quad (9)$$

$$H(t_i, t_z) \leq H(t_i, t_j) + H(t_j, t_z). \quad (10)$$

Both (9) and (10) satisfy the triangle inequality [44], hence the statement holds.  $\square$

Although  $d_2(\cdot, \cdot)$  takes into account the number of genes whose copy numbers have been subjected to a change during the transition from taxon  $t_i$  to taxon  $t_j$ , it does not take into account the value of such a change. For example, consider the following list of three taxa:  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$ ,  $t_2 = \langle 2.2.2.4.4 - 2.2.2 \rangle$  and  $t_3 = \langle 2.2.2.2.6 - 2.2.2 \rangle$ . If we set  $c_1 = 1/8$  and use Equation (7) to compute  $d(t_1, t_2)$  and  $d(t_1, t_3)$  we get  $d(t_1, t_2) = 4.25$  and  $d(t_1, t_3) = 4.125$ . Hence, the transition from  $t_1$  to  $t_3$  is more likely than the transition from  $t_1$  to  $t_2$ . However, as mentioned in the assumptions (vii)-(ix), we consider that the process of gaining three or more copies of any gene in just one generation is an unlikely event. One approach to impose these assumptions consists of penalizing the transitions involving copy number changes greater than one unit. This task can be performed by modifying Equation (7) as follows:

$$d_3(t_i, t_j) = d_2(t_i, t_j) + \sum_{g \in \mathcal{G}: \omega_{ij}^g = 2} c_2 \omega_{ij}^g + \sum_{g \in \mathcal{G}: \omega_{ij}^g = 3} c_3 \omega_{ij}^g + \sum_{g \in \mathcal{G}: \omega_{ij}^g \geq 4} c_4 \omega_{ij}^g, \quad (11)$$

where  $c_k$  satisfying  $c_k \leq c_{k+1}$ ,  $k = 2, \dots, 4$ , are positive constants used to weight the new addends. For example, if  $c_2 = 1/16$ ,  $c_3 = 1/8$  and  $c_4 = 1/5$  then  $d(t_1, t_2) = 4.5$  and  $d(t_1, t_3) = 5.125$ . Thus, the transition from  $t_1$  to  $t_2$  becomes more likely than the transition from  $t_1$  to  $t_3$ .

**Proposition 2.** *The function  $d_3(\cdot, \cdot)$  induces a semimetric space in  $D$ .*

**Proof.** It is easy to see that the non-negativity and the symmetry properties hold for  $d_3(\cdot, \cdot)$ . To see that also the coincidence axiom holds, denote

$$Q_{ij} = \sum_{g \in \mathcal{G}: \omega_{ij}^g = 2} c_2 \omega_{ij}^g + \sum_{g \in \mathcal{G}: \omega_{ij}^g = 3} c_3 \omega_{ij}^g + \sum_{g \in \mathcal{G}: \omega_{ij}^g \geq 4} c_4 \omega_{ij}^g$$

and observe that, for some  $t_i, t_j \in D$ ,  $d_3(t_i, t_j)$  can be written as

$$d_3(t_i, t_j) = d_2(t_i, t_j) + Q_{ij}. \quad (12)$$

If  $t_i = t_j$ , then  $d_2(t_i, t_j) = 0$  and  $Q_{ij} = 0$ . If  $t_i \neq t_j$ , then  $d_2(t_i, t_j) > 0$  and either  $Q_{ij} = 0$  or  $Q_{ij} \geq 0$ . As at least one of the two addends is different from 0, the coincidence axiom holds.

Now observe that  $d_3(\cdot, \cdot)$  does not satisfy the triangle inequality. This fact can be seen by showing a counterexample. Specifically, first note that if the triangle inequality held for  $d_3(\cdot, \cdot)$ , then for some  $t_i, t_j, t_z \in D$ ,  $d_3(t_i, t_j)$  we should have

$$\begin{aligned} d_3(t_i, t_z) &= \|t_i - t_z\|_1 + H(t_i, t_z) + Q(i, z) \\ &\leq \|t_i - t_j\|_1 + H(t_i, t_j) + Q(i, j) + \|t_j - t_z\|_1 \\ &\quad + H(t_j, t_z) + Q(j, z). \end{aligned} \quad (13)$$

Inequality (13) can be seen as the convex combination (with multipliers equal to 1) of the following three inequalities:

$$\|t_i - t_z\|_1 \leq \|t_i - t_j\|_1 + \|t_j - t_z\|_1 \quad (14)$$

$$H(t_i, t_z) \leq H(t_i, t_j) + H(t_j, t_z) \quad (15)$$

$$Q(i, z) \leq Q(i, j) + Q(j, z). \quad (16)$$

The  $L_1$  distance and the Hamming distance satisfy the triangle inequality. However, inequality (16) does not. In fact, if we consider the following three taxa:  $t_1 = \langle 1.1.1.1.1 - 1.1.1 \rangle$ ,  $t_2 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  and  $t_3 = \langle 3.3.3.3.3 - 3.3.3 \rangle$  we have that  $Q(1, 3) = 16c_2 > Q(1, 2) + Q(2, 3) = 0$ . Thus, the statement follows.  $\square$

Semimetrics are particularly interesting to our purposes, as they suggest that transitions from, e.g.,  $t_1 = \langle 1.1.1.1.1 - 1.1.1 \rangle$  to  $t_2 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  and from  $t_2$  to  $t_3 = \langle 3.3.3.3.3 - 3.3.3 \rangle$ , are more likely than the single-step transition from  $t_1$  to  $t_3$ .

It is worth noting that there may exist particular types of transitions that (i) happen in one generation, (ii) involve a large part or all of the genes in  $\mathcal{G}$ , and (iii) are characterized by big copy number changes. For example, when a DLE occurs then it is possible to evolve from  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  to  $t_2 = \langle 4.4.4.4.4 - 4.4.3 \rangle$  in just one generation. We assume that DLE is relatively rare compared to more localized variations and may be not easy to detect. For example, it is not easy to determine whether the pair of taxa  $t_1 = \langle 2.2.2.1.2 - 1.1.1 \rangle$  and  $t_2 = \langle 2.4.4.2.4 - 2.2.2 \rangle$  represent a DLE or arise through two distinct evolutionary processes from the healthy all-2 cell. However, if a DLE was the transition that occurred, Equation (11) would provide  $d(t_1, t_2) = 11.25$  under the assumption that  $c_1 = 1/8$ ,  $c_2 = 1/16$ ,  $c_3 = 1/8$  and  $c_4 = 1/4$ . This value is far larger than the dissimilarity between, e.g.,  $t_1$  and  $t_3 = \langle 3.3.3.2.3 - 2.1.2 \rangle$  under the same cost value (equal to  $d(t_1, t_3) = 7.125$ ). Hence, the transition from  $t_1$  to  $t_2$  would not be considered as likely. To enable identification of possible DLEs in the considered datasets, we modify the dissimilarity measure (11) by adding a new term in (11). Specifically, we denote  $\eta$  as the number of genes whose copy numbers have doubled during the transition from taxon  $t_i$  to taxon  $t_j$  and we set  $\nu = |\mathcal{G}| - \eta$ . Then, we consider the following measure of dissimilarity between taxa  $t_i, t_j \in D$ ,  $i < j$ :

$$\begin{aligned} d_4(t_i, t_j) &= d_3(t_i, t_j) + c_5 \min\{\eta, \nu\} \\ &= d_3(t_i, t_j) + c_5 \min\{\eta, |\mathcal{G}| - \eta\}, \end{aligned} \quad (17)$$

where  $c_5$  is a sufficiently large positive constant such that  $c_5 \gg c_k$ ,  $k = 1, \dots, 4$ . The addend  $c_5 \min\{\eta, |\mathcal{G}| - \eta\}$  constitutes a weighted heuristic approximation of Lee distance [44]. The following proposition holds:

**Proposition 3.** *The function  $d_4(\cdot, \cdot)$  induces a premetric space in  $D$ .*

**Proof.** It is easy to see that the non-negativity and the coincidence axioms hold for  $d_4(\cdot, \cdot)$ . Since the triangle inequality does not hold for  $d_3(\cdot, \cdot)$ , then  $d_4(\cdot, \cdot)$  does not induce a metric space either. To see that also the symmetry property does not hold for  $d_4(\cdot, \cdot)$  it is sufficient to consider taxa  $t_1 = \langle 2.2.2.2.2 - 1.1.1 \rangle$  and  $t_2 = \langle 1.1.4.4.4 - 2.1.1 \rangle$  and to observe that  $d_4(t_1, t_2) = d_3(t_1, t_2) + 4c_5$  and  $d_4(t_2, t_1) = d_3(t_2, t_1) + 2c_5 = d_3(t_1, t_2) + 2c_5$ .  $\square$

Premetrics are useful for our purposes as, in our classification attempt, we consider DLEs as *directional evolutionary processes*, i.e., processes that consider the transition from taxon  $t_i$  to  $t_j$  and from taxon  $t_j$  to  $t_i$  as two events having different probabilities. It is also worth noting that  $d_4(\cdot, \cdot)$  models the assumption that a duplication event followed by some loss or (few) gain events is more probable than a large number of sequential gain or loss events. For example,  $d_4(\cdot, \cdot)$  indicates that the transition, e.g., from  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  to  $t_2 = \langle 4.4.4.4.4 - 4.4.3 \rangle$  is more likely to

have occurred in two events (e.g., from  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  to  $t_k = \langle 4.4.4.4.4 - 4.4.4 \rangle$  and then from  $t_k$  to  $t_2 = \langle 4.4.4.4.4 - 4.4.3 \rangle$ ) rather than in a sequence of transitions in which at each step a copy number of a gene increase (e.g., from  $t_1 = \langle 2.2.2.2.2 - 2.2.2 \rangle$  to  $t_{k_1} = \langle 3.2.2.2.2 - 2.2.2 \rangle$ , from  $t_{k_1}$  to  $t_{k_2} = \langle 3.3.2.2.2 - 2.2.2 \rangle$ , and so on, until the transition from  $t_{k_q} = \langle 4.4.4.4.4 - 4.3.3 \rangle$  to  $t_{k_2} = \langle 4.4.4.4.4 - 4.4.3 \rangle$ ). In the remainder of the article, we shall use  $d_4(\cdot, \cdot)$  to measure the dissimilarity between a pair of taxa in  $D$  and for simplicity of notation we will write  $d_4(t_i, t_j)$  as  $d_{ij}$ .

### 3.3 Using Integer Programming to Predict the Progression of Ductal Carcinoma under the Parsimony Criterion

In this section, we formalize the parsimony criterion in terms of an optimization problem on a graph. To this end, given a set  $D$  of single-cell sample data extracted from a patient, consider a complete undirected weighted graph  $G = (V, E)$ , called *tumor graph*, having a vertex  $i$  for each taxon  $t_i \in D$  and a weight  $d_{ij}$  for each edge  $(i, j) \in E$ . We assume that vertex 1 represents the healthy taxon  $\langle 2.2.2.2.2 - 2.2.2 \rangle$ , i.e., the origin of progression, and we define  $V_1 = V \setminus \{1\}$ . Then, predicting the progression of ductal carcinoma from  $D$  via the parsimony criterion is equivalent to solving the following problem:

**Problem (The Parsimonious Tumor Progression Problem (PTPP)).** Given a set  $D$  of single-cell sample data extracted from a patient and the corresponding tumor graph  $G = (V, E)$ , find an arborescence rooted in vertex 1, covering all of the remaining vertices in  $V_1$ , satisfying the assumptions discussed in Section 2.2, and such that the sum of the distances among all pairs of adjacent taxa in the arborescence is minimized.  $\square$

It is worth noting that the PTPP cannot be trivially solved by means of classical hierarchical clustering algorithms such as UPGMA [43]. In fact, in classical molecular phylogenetics the observed taxa can only be terminal vertices of a phylogeny; the internal vertices represent speciation events occurred along evolution of taxa are usually assumed to be non-contemporary to them. In contrast, in tumorigenesis, ancestor and descendant clones may co-exist throughout tumor progression [23]. This fact alone suggests that a phylogeny obtained via traditional clustering algorithms may not constitute a suitable representation of a tumorigenesis. Similarly, the PTPP cannot be trivially solved by using any greedy algorithm for the minimum spanning tree [45], at least because the solutions provided by these algorithms may not satisfy the assumptions (iv)-(v).

A possible approach to solve PTPP consists of using Integer Linear Programming, which provides both a powerful tool to model the assumptions in Section 2.2 and a certificate of optimality for the solution to the PTPP so computed. In particular, the presence of the assumption (v) may require the use of ILP formulations based on path variables and solvable via column generation approaches and branch-and-price methods similar to those described, for example, in [46]. However, we have observed that the strict temporal progression assumption (v) does not quite match the study design of [23]. In fact, the DCIS and IDC single-cell samples

extracted from each patient were physically sampled at the same time. Even if the assumption that the DCIS state strictly precedes the IDC state is completely correct at the single-cell level, the transformation from DCIS to IDC must have happened at an earlier point in time when the DCIS was in a precursor state  $P$  of the sampled state. Since gene copy number changes are likely to have occurred between  $P$  and the sampled DCIS, the cells containing these late changes will not be temporal predecessors of cells in the sampled IDC. For example, in the dataset DAT10 (see Fig. 10 in supplementary data downloadable at [perso.uclouvain.be/daniele.catanzaro/SupportingMaterial/IDC.pdf](http://perso.uclouvain.be/daniele.catanzaro/SupportingMaterial/IDC.pdf)) the IDC taxon  $\langle 2.2.2.2.2 - 3.2.2 \rangle$  would be obliged to appear in progression later than DCIS taxa  $\langle 2.2.2.3.2 - 2.2.2 \rangle$  and  $\langle 2.2.2.2.2 - 2.3.2 \rangle$  even if it seems to be contemporaneous with them. Moreover, this fact leads us to suspect the possibility that the causes underlying the progression from DCIS to IDC may not be exclusively restricted to the eight genes considered in [23]. Hence, we decided to relax the strict temporal progression assumption (v) along a path by transforming it into an absence of alternating invasive/non-invasive states, i.e., an absence in the arborescence of three contiguous vertices  $i \neq j \neq k \in V$  such that  $i$  precedes  $j$ ,  $j$  precedes  $k$ , and such that the corresponding taxa satisfy the following property:  $t_i \in IDC$ ,  $t_j \in ISL$  and  $t_k \in DCIS$ . Moreover, we decided to relax the absence in the arborescence of pairs of taxa belonging to  $R_3 \cup R_4 \cup R_5$  by penalizing their existence by means of a particular cost in the objective function. Specifically, we add in (17) the addend  $c_6 \lambda_{ij}$ , where  $c_6 \geq c_5$ , and

$$\lambda_{ij} = \begin{cases} \sum_{g \in \mathcal{G}} \omega_{ij}^g & (t_i, t_j) \in \bigcup_{s=3}^5 R_s, \\ 0 & \text{otherwise.} \end{cases}$$

Then, a possible ILP formulation for the PTPP is the following:

#### Formulation

$$\min \sum_{i,j \in V: i \neq j} (d_{ij} + c_6 \lambda_{ij}) y_{ij} \quad (18a)$$

$$y_{ij} = 0 \quad \forall i, j \in V : (i, j) \in R_1 \cup R_2 \quad (18b)$$

$$y_{ij} + y_{jk} \leq 1 \quad \forall i < j < k \in V_1 : \begin{aligned} & t_i \in IDC, \\ & t_j \in ISL, \\ & t_k \in DCIS \end{aligned} \quad (18c)$$

$$\sum_{i,j \in S: i \neq j} y_{ij} \leq |S| - 1 \quad \forall S \subset V, S \neq \emptyset \quad (18d)$$

$$\sum_{i,j \in V: i \neq j} y_{ij} = |V| - 1 \quad (18e)$$

$$y_{j1} = 0 \quad \forall j \in V_1 \quad (18f)$$

$$y_{ij} \in \{0, 1\} \quad \forall i, j \in V : i \neq j. \quad (18g)$$

$\square$

Constraints (18b) impose the absence of pairs of adjacent vertices in the arborescence belonging to  $R_1 \cup R_2$ , i.e., pairs of taxa violating either the *ex nihilo nihil* assumption or the strict temporal progression assumption (v) in a direct transition from ancestor to descendent. Constraints (18c) impose the absence of oscillating invasive/non-invasive states. Constraints (18d) impose the absence of cycles in the arborescence. Constraint (18e) imposes that the overall number of arcs in the arborescence is  $|V| - 1$ . Finally, constraints (18f) impose the absence of incoming arcs for vertex 1.

## 4 NUMERICAL EXPERIMENTS

To test the predictions provided by Formulation 3.2 we reanalyzed the [23] datasets obtained from a population of 13 individuals affected by invasive ductal carcinoma of the breast. For completeness, we report in Table 1 a simple description of each dataset in terms of the number of DCIS and IDC single-cell taxa. We refer the interested reader to [23] for a more extensive and systematic description of the datasets.

We implemented Formulation 3.2 in ANSI C++ by using Xpress Optimizer libraries v18.10.00. The experiments were run on a Pentium 4, 3.2 GHz, equipped with 2 GByte RAM and operating system Gentoo release 7 (Linux kernel 2.6.17). When solving the instances of Formulation 3.2, we activated Xpress automatic cuts, Xpress pre-solving strategy, and used Xpress primal heuristic to generate the first upper bound for the problem. We did not limit the computation time of the above Formulation because time is not a hard constraint for this application.

As progression of a tumor in a patient usually is an unobservable process, there is no general way to validate empirically a candidate set of costs for the dissimilarity measure proposed in (17). After a number of preliminary attempts aiming to obtain a measure able both to provide integer values and to guarantee the respect of the hierarchical assumptions described in Section 2.2, we set the costs in (17) as follows:  $c_1 = 30$ ,  $c_2 = 60$ ,  $c_3 = 90$ ,  $c_4 = 500$ ,  $c_5 = c_6 = 1,000$ . However, we observe that this is not the only possible choice and that there exist alternative measures of dissimilarities that could be considered as plausible as the one proposed in this article. For example, an alternative measure of the dissimilarity between taxa  $t_i, t_j \in D$ ,  $i < j$ , could be obtained by maximizing the likelihood related to the transition from a taxon  $t_i$  to  $t_j$ , under the hypothesis that the copy number of each gene changes independently of the others. This task could be performed, e.g., by solving the following optimization problem:

$$\max d(t_i, t_j) = \prod_{g \in \mathcal{G}} p_u^{\alpha_{ij}^g} \cdot p_i^{\beta_{ij}^g} \cdot p_d^{\gamma_{ij}^g} \quad (19a)$$

$$s.t. \quad p_u + p_i + p_d = 1 \quad (19b)$$

$$p_s \geq 0 \quad \forall s \in \{u, i, d\}, \quad (19c)$$

where  $p_u$  is the probability that the copy number of gene  $g$  remains unchanged in the transition from taxon  $t_i$  to taxon  $t_j$ ;

$p_i$  is the probability that the copy number of gene  $g$  increases in the transition from taxon  $t_i$  to taxon  $t_j$ ;  $p_d$  is the probability that the copy number of gene  $g$  decreases in the transition from taxon  $t_i$  to taxon  $t_j$ ;  $\alpha_{ij}^g$  is a positive number equal to 1 if the copy number of gene  $g$  remains unchanged in the observed transition from taxon  $t_i$  to taxon  $t_j$  and 0 otherwise;  $\beta_{ij}^g$  is a positive number equal to  $\omega_{ij}^g$  if the copy number of gene  $g$  increases in the observed transition from taxon  $t_i$  to taxon  $t_j$  and 0 otherwise; and  $\gamma_{ij}^g$  is a positive number equal to  $\omega_{ij}^g$  if the copy number of gene  $g$  decreases in the observed transition from taxon  $t_i$  to taxon  $t_j$  and 0 otherwise.

The likelihood-based approach entails the quantification of the assumptions described in Section 2.2 and the expression of these assumptions in terms of constraints for Problem (19a)-(19c). We did not investigate the likelihood-based approach much further, as studying alternative measures of dissimilarity for the considered FISH data is not the main scope of the present article. Here, we merely observe that the likelihood-based approach and the measures of dissimilarities discussed in Section 3.2 are related. In fact, for fixed values of the probabilities  $p_u$ ,  $p_i$  and  $p_d$ , the logarithm base (e.g.,  $p_i$ ) of the objective function in the likelihood-based approach becomes

$$\sum_{g \in \mathcal{G}} \left( \alpha_{ij}^g \log_{p_i}(p_u) + \beta_{ij}^g + \gamma_{ij}^g \log_{p_i}(p_d) \right). \quad (20)$$

Whenever the logarithms are defined in (20), the addend  $\alpha_{ij}^g \log_{p_i}(p_u) + \beta_{ij}^g + \gamma_{ij}^g \log_{p_i}(p_d)$  would add

$$\begin{cases} K_1 & \text{if } |t_i^g - t_j^g| = 0 \\ |t_i^g - t_j^g| & \text{if } |t_i^g - t_j^g| > 0 \\ |t_i^g - t_j^g| K_2 & \text{if } |t_i^g - t_j^g| < 0, \end{cases} \quad (21)$$

where  $K_1 = \log_{p_i}(p_u)$  and  $K_2 = \log_{p_i}(p_d)$  are two positive constants. This fact shows one relationship between the likelihood-based approach and, e.g.,  $d_1(\cdot, \cdot)$ . Similar relationships exist also for  $d_k(\cdot, \cdot)$ ,  $k \in \{2, 3, 4\}$ . Investigating further these relationships warrants additional analysis.

## 5 RESULTS AND DISCUSSION

Figs. 1, 2, and 3 show examples of predicted progression trees for three paired DCIS/IDC cases, provided to illustrate some of the similarities and differences between inferred phylogenies by dataset. The remaining full trees are omitted in the main manuscript for brevity, but can be found in the supplementary data downloadable at [perso.uclouvain.be/daniele.catanzaro/SupportingMaterial/IDC.pdf](http://perso.uclouvain.be/daniele.catanzaro/SupportingMaterial/IDC.pdf).

A few general trends are apparent from manual examination of the trees. The progression of the IDC is characterized by an elevated tendency to lose copies of *TP53* ( $17.79\% \pm 5.11\%$ ) and other tumor suppressor genes ( $36\% \pm 5.35\%$ ). Moreover, the tumor suppressor genes have a high level of *spontaneous variation* (see Fig. 4), i.e., the tendency of a single gene in a taxon to increase or decrease its copy number with respect to its immediate ancestor while the copy numbers of the remaining genes in both taxa are unchanged. *CDH1* shows the highest average rate of spontaneous variation ( $16.53 \pm 6.59$ ), followed by *TP53* ( $15.36 \pm 5.18$ ) and *DBC2* ( $14.23 \pm 6.51$ ). Among the oncogenes, *COX2*




Fig. 1. Predicted progression from DCIS to IDC for the dataset DAT01. For ease of interpretation, each sample is represented by a sequence of numbers separated by dots and a dash. Specifically, the first five numbers represent the copy numbers for the oncogenes *COX2*, *MYC*, *HER2*, *CCND1*, and *ZNF217* and the last three numbers represent the copy numbers for the tumor suppressor genes *DBC2*, *CDH1*, and *TP53*. The samples in black and red refer to DCIS or IDC single cells, respectively. The samples in blue refer to single cells found in both DCIS and IDC.

shows the highest level of spontaneous variation ( $13.19 \pm 6.02$ ), followed by *ZNF217* ( $10.75 \pm 6.07$ ), *CCND1* ( $10.13 \pm 4.69$ ), *HER2* ( $10.03 \pm 3.33$ ) and *MYC* ( $9.79 \pm 3.87$ ). Interestingly, *ZNF217* is more prone to spontaneous variations in datasets DAT07 and DAT09 and this phenomenon seems to be correlated to the variation induced by *CDH1* (see Figs. 22 and 24 in supplementary data, available online). The doubling-loss event is less frequent ( $7\% \pm 3.99\%$ ) than loss of tumor suppressor genes. It also appears to be more specific to particular datasets than others.

We offer a tentative classification of the datasets in Table 2, manually clustering the datasets based on apparent genetically distinct subsets of tumors. Specifically, we can distinguish between progressions showing a preponderance of doubling-loss phenomena (“Doubling-Driven” column in Table 2) and progressions showing a low or absent presence of the doubling-loss event (“Doubling-Absent” column in Table 2). The first group is the largest and can be in turn subdivided in three main subgroups, namely: the *regular*, the *abnormal-with-TP53-predominance* and the *abnormal-with-CDH1-predominance*. The regular group is the largest subgroup and includes datasets DAT02 (Fig. 2), DAT03, DAT04, DAT11, DAT12 and DAT13. As a general trend, this group shows a high spontaneous variation, usually affecting the tumor suppressor genes *CDH1* and *TP53*, which in general tend to be lost. Moreover, the copy numbers of the

genes in general do not tend to increase with respect to the root node to a similar degree as is seen in the abnormal groups and usually do not exceed eight copies. The doubling-loss event is more predominant in the regular group than in others, it usually tends to affect (almost) all genes (see, e.g., taxa  $\langle 2.2.2.1.2 - 1.1.1 \rangle$  and  $\langle 4.4.4.2.4 - 2.2.2 \rangle$ , or  $\langle 2.3.2.1.2 - 1.1.1 \rangle$  and  $\langle 4.6.4.2.4 - 1.2.2 \rangle$  in Fig. 2). It can be considered as a possible driving mechanism of progression of the carcinoma, being located in several internal vertices of corresponding predictions.

The abnormal-with-*TP53*-predominance subgroup includes datasets DAT08 and DAT06 (Fig. 3). It is characterized by a very high spontaneous variation for *TP53* with frequent loss either of the tumor suppressor gene *CDH1* if *DBC2* is affected by high spontaneous variations or, vice versa, loss of the tumor suppressor gene *DBC2* if *CDH1* is affected by high spontaneous variations. The copy number of the genes tends to increase more than in the other categories, but usually does not exceed 8 copies. The instance DAT06 shows multiple situations in which some or all of the tumor suppressor genes are lost and this phenomenon usually comes together with a simultaneous loss of one or more oncogenes. A similar situation can be observed also in DAT08 (see supplementary data, available online), although the loss of gene copies is less predominant. Interestingly, dataset DAT08 shows a very high level of variation of *TP53* with




Fig. 2. Predicted progression from DCIS to IDC for the dataset DAT02.

copy numbers ranging from 0 to 5. This fact seems to suggest the presence of a strong selective pressure acting on this gene. Similarly, in both datasets, *COX2* and *MYC* show a high level of variation, particularly *COX2*, although with a tendency towards gain or doubling events. The doubling-loss event is less preponderant in these tumors than in the regular subgroup and it is “abnormal” in the sense that it usually does not affect all of the genes but just some of the genes (see, e.g., taxa  $\langle 4.2.2.2.3 - 2.2.2 \rangle$  and  $\langle 5.4.3.4.1 - 2.2.3 \rangle$  in Fig. 3 or taxa  $\langle 2.2.2.2.2 - 1.1.2 \rangle$  and  $\langle 4.2.2.2.2 - 2.1.3 \rangle$  in Fig. 8 of supplementary data, online available). Also in this case, the doubling-loss event can be considered as a possible source of progression of the carcinoma, being located in several internal vertices of corresponding predictions.

The abnormal-with-*CDH1*-predominance subgroup includes datasets DAT01 (Fig. 1), DAT07, and DAT09. It is characterized by a very high spontaneous variation of *CDH1* with respect to *TP53*, high spontaneous variation of *CCND1* and *ZNF217*, and a low tendency to lose tumor suppressor genes. This subgroup shows the highest absolute gene copy numbers, with some single oncogenes showing copy numbers up to 25 in single cells (see, e.g., DAT07 in supplementary data, available online). The doubling-loss event is still present, although to a lesser degree than in the previous two subgroups.

Finally, the doubling-absent subgroup includes datasets DAT05 and DAT10. It is characterized by a very high spontaneous variation of *CDH1*, high spontaneous variation of

*COX2* and *MYC*, and a low tendency to lose tumor suppressor genes. This subgroup does not show a significant presence of doubling-loss phenomena, although some genes (namely, *COX2* and *MYC*) tend to acquire high copy numbers with respect to the root, especially in DAT10. Specifically, in this dataset progression of the carcinoma seems to be caused by iterated increments of *COX2* over time, which seems to be associated with variation in the copy number of *CDH1*.

The apparent subgrouping of tumors suggests variations patient to patient, not just in random accumulation of mutations, but also in the phenotype for generating mutations. More specifically, distinct subsets of tumors show preferences for generation of aneuploidy versus amplification or loss of specific driver genes as well as in the selection of driver genes. These results are consistent with both a generic driver-passenger model, in which defined subtypes of tumors arise due to recurrent selection for malformations that produce specific selective advantages to tumors [47], [48], and with the mutator phenotype model, in which distinct subsets of tumors are driven by distinct mechanisms of generating genetic diversity [49]. In evolutionary terms, our results suggest intra-cellular heterogeneity is driven by variability in both mechanisms of diversification and selection for specific driver genes.

In principle, predicting tumor progression from single-cell sample data extracted from an individual is not a time-sensitive application. However, exploring the relationships between the computation times of Formulation (18) and the




Fig. 3. Predicted progression from DCIS to IDC for the dataset DAT06.

size of the instances of the problem may provide a better understanding of the computational performance of Formulation (18). As single-cell sample data are currently very difficult to obtain, we decided to consider a set of artificial instances of the problem characterized by 100, 150, 200, 250 and 300 taxa, respectively. For a fixed size (number of taxa)  $t \in \{100, 150, 200, 250, 300\}$  we generated 20 random arborescences, each rooted in the healthy taxon and spanning  $t$  vertices. The algorithm used to generate a generic random arborescence  $T$  consisted of repeating the following steps: (i) given a vertex  $i$ , generate  $k$  children of  $i$ ,  $k$  being a pseudorandom integer in  $[0, 10]$ ; (ii) select a random vertex of  $T$  and repeat step (i) until  $t$  vertices are generated. In our experiments, we used the Mersenne twister library [50] as the pseudorandom generator. For each random arborescence  $T$ , we simulated the progression of tumor cells by randomly choosing on each arc  $(i, j)$  of  $T$  the type of mutation on vertex  $j$  (namely, copy number increment, copy number decrement and pure doubling) and the genes involved in the mutation. Specifically, we first set taxon  $j$  equal to its ancestor  $i$ . Subsequently, we set the probabilities of having a copy number increment, a copy number decrement and a pure doubling phenomenon roughly similar to the average frequencies of observing those phenomena in the considered real datasets (namely 0.84, 0.15 and 0.01, respectively). Then, we generated a random number  $r$  in  $[0, 1]$  and used this value to determine the type of mutation on taxon  $j$ . In particular, we used the following three cases: if  $r \leq 0.84$  an

increment of gene copy number arises; if  $0.84 < r \leq 0.99$  a decrement of gene copy number arises; if  $r > 0.99$  a pure doubling phenomenon arises. If the selected type of mutation is an increment or a decrement of gene copy number, the number of genes and the genes themselves subjected to the corresponding mutation are randomly chosen according to the following rules: (i) the number of selected genes cannot exceed 3; (ii) the ex nihilo nihil assumption has to be satisfied in the transition from taxon  $i$  to taxon  $j$ ; (iii) the increment (or decrement) of gene copy number




Fig. 4. Predicted spontaneous variation of the gene copy number (expressed in percentage) in the considered datasets.

TABLE 2  
A Possible Classification of the Analyzed Datasets

Regular	Doubling-Driven		Doubling-Absent
	Abnormal		
	<i>TP53</i> -driven	<i>CDH1</i> -driven	
DAT02	DAT06	DAT01	DAT05
DAT03	DAT08	DAT07	DAT10
DAT04		DAT09	
DAT11			
DAT12			
DAT13			

cannot exceed 2. If the selected type of mutation is a pure doubling, then the copy numbers of all genes (but *TP53*) of vertex  $j$  are doubled and the copy number of *TP53* is increased by 1 unit. Finally, the nature of taxon  $j$  (i.e., whether it belongs to *DCIS*, *ISI* or *IDC*) is randomly determined by strictly respecting the temporal progression. Fig. 5 shows the average computation times taken by Formulation (18) to solve the random instances so generated. The five average computation times fit a polynomial function of the number of taxa, with exponent approximately 2 (i.e., quadratic). At present, this is not a serious issue, as extracting large size single-cell sample datasets from patients is expensive and datasets containing more than 300 taxa are rarely analyzed. However, it reasonable to believe that in the coming years the cost for extracting single-cell sample data from patients will decrease; hence, datasets of larger and larger size will become more and more common. Therefore, investigating alternative ILP formulations able to reduce the solution time necessary to analyze a large dataset deserves further research efforts.

## 6 CONCLUSION

We proposed an approach to reconstruct a plausible progression of ductal carcinoma from single-cell sampled data of an affected individual. The approach is based on combining a generic parsimony model for evolutionary tree inference with a complex set of system-specific assumptions derived from prior knowledge regarding cellular atypia occurring in ductal carcinoma. ILP tools provide a way to describe and efficiently solve for optimal tree models in the presence of such complex constraints. Given the enormous variability between tumor types and study designs, our ILP strategy may have much broader utility for interpreting complex cellular variation data with reference to complicated system-specific biological constraints. While some aspects of our specific constraint sets are likely to be applicable across broad classes of tumor types (e.g., modeling the role of *TP53* in chromosome instability or imposing timing constraints on defined pre-cancerous and cancerous progression stages), though, we do expect that some problem-specific expertise is likely to be needed to develop comparable approaches for other tumor progression systems. For example, we have studied another data collection of paired samples with single-cell FISH data on cervical cancer in which the pairs are from the primary tumor and from a metastasis [15]. For such a primary/metastasis study design, progression models




Fig. 5. Average computation times taken by Formulation (18) to solve instances of the problem containing 100, 150, 200, 250, and 300 taxa, respectively. The vertical bars indicate the standard deviations.

could give insight into what evolutionary changes allow the metastatic sample to spread. The genes selected for FISH analysis in the cervical cancer data mostly differ from the genes in the DCIS/IDC, so one would need to adapt our modeling here to the cancer characteristics of the genes evaluated by FISH in that other data collection.

Our model suggests that progressions estimated from a population of 13 affected individuals are non-random and classifiable into several categories seemingly distinguished by distinct selective pressures and distinct mechanisms for generating genetic diversity. The complex and heterogeneous evolutionary landscape they reveal may have important implications for strategies for cancer treatment. In particular suggesting that developing effective therapies may require considering both the current spectrum of driver mutations in a tumor and the mutator phenotype by which it is generating diversity. For example, Martins et al. [11] point out that whether a breast cancer patient is a good candidate for drugs that inhibit PARP is currently thought to depend on whether the patient's cancer genome has a defect in DNA damage repair leading to genomic instability.

## ACKNOWLEDGMENTS

This research was supported in part by the Belgian National Fund for Scientific Research (FRS-FNRS) (D.C), US National Institutes of Health grants 1R01CA140214 (R.S.) and 1R01AI076318 (R.S.), and the Intramural Research Program of the NIH, NLM (A.A.S.). The authors thank the anonymous reviewers whose insightful suggestions helped them improve the manuscript.

## REFERENCES

- [1] G. von Minckwitz, S. Darb-Esfahani, S. Loibl, J. Huober, H. Tesch, C. Solbach, F. Holms, H. Eidtmann, K. Dietrich, M. Just, M. Clemens, C. Hanusch, I. Schrader, S. Henschel, G. Hoffmann, K. Tiemann, K. Diebold, M. Untch, and C. Denkert, "Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40)," *Breast Cancer Res. Treatment*, vol. 132, pp. 863–870, 2012.

- [2] D. C. Sgroi, "Preinvasive breast cancer," *Annu. Rev. Pathol.*, vol. 5, pp. 193–221, 2010.
- [3] B. A. Virnig, T. M. Tuttle, T. Shamliyan, and R. L. Kane, "Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes," *J. Nat. Cancer Inst.*, vol. 102, no. 3, pp. 170–178, 2010.
- [4] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," *CA A Cancer J. Clinicians*, vol. 61, pp. 69–90, 2011.
- [5] J. J. Fenton, G. Xing, J. G. Elmore, H. Bang, S. L. Chen, K. K. Lindfors, and L. Baldwin, "Short-term outcomes of screening mammography using computer-aided detection: A population-based study of medicare enrollees," *Ann. Intern. Med.*, vol. 158, no. 8, pp. 580–587, 2013.
- [6] G. Pennington, C. A. Smith, S. Shackney, and R. Schwartz, "Cancer phylogenetics from single-cell assays," Dept. Comput. Sci., Pittsburgh, PA, USA, Carnegie Mellon Univ., Tech. Rep. CMU-CS-06-103, 2006.
- [7] G. Pennington, C. A. Smith, S. Shackney, and R. Schwartz, "Reconstructing tumor phylogenies from heterogeneous single-cell data," *J. Bioinform. Comput. Biol.*, vol. 5, no. 2a, pp. 407–427, 2006.
- [8] D. Frumkin, A. Wasserstrom, S. Itzkovitz, T. Stern, A. Harmelin, R. Eilam, G. Rechavi, and R. Shapiro, "Cell lineage analysis of a mouse tumor," *Cancer Res.*, vol. 68, pp. 5924–5931, 2008.
- [9] E. Letouzé, Y. Allory, M. A. Bollet, F. Radvanyi, and F. Guyon, "Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis," *Genome Biol.*, vol. 11, p. R76, 2010.
- [10] M. Rieder, C. S.-O. Attolini, R. J. Downey, S. Singer, and F. Michor, "A differentiation-based phylogeny of cancer subtypes," *PLoS Comput. Biol.*, vol. 6, article e100077, 2010.
- [11] F. C. Martins, S. De, V. Almendro, M. Gönen, S. Y. Park, J. L. Blum, W. Herlihy, G. Ethington, S. J. Schnitt, N. Tung, J. E. Garber, K. Fettes, F. Michor, and K. Polyak, "Evolutionary pathways in BRCA1-associated breast tumors," *Cancer Discovery*, vol. 2, no. 6, pp. 503–511, 2012.
- [12] O. Podlaha, M. Rieder, S. De, and F. Michor, "Evolution of the cancer genome," *Cell*, vol. 28, no. 4, pp. 155–163, 2012.
- [13] L. I. Shlush, N. Chapal-Ilani, R. Adar, N. Pery, Y. Maruvka, A. Spiro, R. Schouval, J. M. Rowe, M. Tzukerman, D. Bercovich, S. Izraeli, G. Marcucci, C. D. Bloomfield, T. Zuckerman, K. Skorecki, and E. Shapiro, "Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability," *Blood*, vol. 120, pp. 603–612, 2012.
- [14] K. I. Kim and R. Simon, "Using single cell sequencing data to model the evolutionary history of a tumor," *BMC Bioinform.*, vol. 15, no. 27, 2014.
- [15] S. A. Chowdhury, S. Shackney, K. Heselmeyer-Haddad, T. Ried, A. A. Schäffer, and R. Schwartz, "Phylogenetic analysis of multiprobe fluorescence in situ hybridization data from tumor cell populations," *Bioinformatics*, vol. 29, no. 13, pp. i189–i198, 2013.
- [16] S. A. Chowdhury, S. Shackney, K. Heselmeyer-Haddad, T. Ried, A. A. Schäffer, and R. Schwartz, "Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics," *PLoS Comput. Biol.*, vol. 10, no. 7, article e1003740, <http://reports-archive.adm.cs.cmu.edu/anon/2006/CMU-CS-06-103.pdf>, 2014.
- [17] C. S. O. Attolini and F. Michor, "Evolutionary theory of cancer," *Ann. New York Acad. Sci.*, vol. 1168, pp. 23–51, 2009.
- [18] N. Beerenwinkel, R. F. Schwartz, M. Gerstung, and F. Markowetz, "Cancer evolution: Mathematical models and computational inference," *Syst. Biol.*, vol. 64, no. 1, pp. e1–e25, 2015.
- [19] T. Kainu, S. Juo, R. Desper, A. A. Schäffer, E. Gillanders, E. Rozenblum, D. Freas-Lutz, D. Weaver, D. Stephan, J. Bailey-Wilson, O. Kallioniemi, M. Tirkkonen, K. Syrjäkoski, T. Kuukasjärvi, P. Koivisto, R. Karhu, K. Holli, A. Arason, G. Johannesdottir, J. T. Bergthorsson, H. Johannesdottir, V. Egilsson, R. B. Barkardottir, O. Johannsson, K. Haraldsson, T. Sandberg, E. Holmberg, H. Grönberg, H. Olsson, Å. Borg, P. Vehmanen, H. Eerola, P. Heikkilä, S. Pyrhönen, and H. Nevanlinna, "Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus," in *Proc. Nat. Acad. Sci. USA*, vol. 97, pp. 9603–9608, 2000.
- [20] N. Navin, J. K. Abd J. Troge, P. Andrews, L. Rodgers, J. McIndoo, K. Cook, A. Stepansky, D. Levy, D. Esposito, L. Muthuswamy, A. Krasnitz, W. R. McCombie, J. Hicks, and M. Wigler, "Tumour evolution inferred by single-cell sequencing," *Nature*, vol. 472, no. 7341, pp. 90–94, 2011.
- [21] T. Baslan, J. Kendall, L. Rodgers, H. Cox, M. Riggs, A. Stepansky, J. Troge, K. Ravi, D. Esposito, B. Lakshmi, M. Wigler, N. Navin, and J. Hicks, "Genome-wide copy number analysis of single cells," *Nature Protocols*, vol. 7, pp. 1024–1041, 2012.
- [22] H. Zare, J. Wang, A. Hu, K. Weber, J. Smith, D. Nickerson, C. Song, D. Witten, C. A. Blau, and W. S. Noble, "Inferring clonal composition from multiple sections of a breast cancer," *PLoS Comput. Biol.*, vol. 10, article e1003703, 2014.
- [23] K. Heselmeyer-Haddad, L. Y. B. Garcia, A. Bradley, C. Ortiz-Melendez, W. J. Lee, R. Christensen, S. A. Prindiville, K. A. Calzone, P. W. Soballe, Y. Hu, S. A. Chowdhury, R. Schwartz, A. A. Schäffer, and T. Ried, "Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity, yet conserved genomic imbalances and gain of MYC during progression," *Am. J. Pathol.*, vol. 181, no. 5, pp. 1807–1822, 2012.
- [24] V. Almendro, Y. K. Cheng, A. Randles, S. Itzkovitz, A. Marusyk, E. Ametller, X. Gonzalez-Farre, M. Muñoz, H. G. Russnes, E. Helland, I. H. Rye, A. L. Borresen-Dale, R. Maruyama, A. van Oudenaarden, M. Dowsett, R. L. Jones, J. Reis-Filho, P. Gascon, M. Gönen, F. Michor, and K. Polyak, "Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of cellular diversity for genetic and phenotypic features," *Cell Rep.*, vol. 6, no. 3, pp. 514–527, 2014.
- [25] E. Pennisi, "Single-cell sequencing tackles basic and biomedical questions," *Science*, vol. 336, no. 6048, pp. 976–977, 2012.
- [26] A. Marusyk and K. Polyak, "Tumor heterogeneity: Causes and consequences," *Biochim. Biophys. Acta Rev. Cancer*, vol. 1805, no. 1, pp. 105–117, 2010.
- [27] M. Gerlinger, A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N. Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C. R. Santos, M. Nohadani, A. C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. A. Futreal, and C. Swanton, "Intratumor heterogeneity and branched evolution revealed by multiregion sequencing," *New England J. Med.*, vol. 366, no. 10, pp. 883–892, 2012.
- [28] A. Sottoriva, I. Spiteri, S. G. Piccirillo, A. Touloumis, V. P. Collins, J. C. Marioni, C. Curtis, C. Watts, and S. Tavaré, "Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics," *Proc. Nat. Acad. Sci. USA*, vol. 110, no. 10, pp. 4009–4014, 2010.
- [29] M. Snuderl, L. Fazlollahi, L. P. Le, M. Nitta, B. H. Zhelyazkova, C. J. Davidson, S. Akhavanfard, D. P. Cahill, K. D. Aldape, R. A. Betensky, D. N. Louis, and A. J. Iafrate, "Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma," *Cancer Cell*, vol. 20, no. 6, pp. 810–817, 2011.
- [30] N. J. Szerlip, A. Pedraza, D. Chakravarty, M. Azim, J. McGuire, Y. Fang, T. Ozawa, E. C. Holland, J. T. Huse, S. Jhanwar, M. A. Leversha, T. Mikkelsen, and C. W. Brennan, "Intratumor heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response," in *Proc. Nat. Acad. Sci. USA*, vol. 109, no. 8, pp. 3041–3046, 2012.
- [31] K. Sprouffske, J. W. Pepper, and C. C. Maley, "Accurate reconstruction of the temporal order of mutations in neoplastic progression," *Cancer Prevention Res.*, vol. 4, no. 7, pp. 1135–1144, 2011.
- [32] H. S. Farahani and J. Lagergren, "Learning oncogenetic networks by reducing to MILP," *PLoS ONE*, vol. 8, article e65773, 2013.
- [33] L. Sontag and D. E. Axelrod, "Evaluation of pathways for progression of heterogeneous breast tumors," *J. Theoretical Biol.*, vol. 232, no. 2, pp. 179–189, 2005.
- [34] S. Lin, "Mixture modeling of progression pathways of heterogeneous breast tumors," *J. Theoretical Biol.*, vol. 249, no. 2, pp. 254–261, 2007.
- [35] N. Beerenwinkel, J. Rahnenführer, R. Kaiser, D. Hoffmann, J. Selbig, and T. Lengauer, "Mtreemix: A software package for learning and using mixture models of mutagenetic trees," *Bioinformatics*, vol. 21, no. 9, pp. 2106–2107, 2005.
- [36] D. Tolliver, C. Tsourakakis, A. Subramanian, S. Shackney, and R. Schwartz, "Robust unmixing of tumor states in array comparative genomic hybridization data," *Bioinformatics*, vol. 26, no. 12, pp. 89–102, 2010.
- [37] A. Efeyan and M. Serrano, "P53: Guardian of the genome and policeman of the oncogenes," *Cell Cycle*, vol. 6, no. 9, pp. 1006–1010, 2007.

- [38] K. K. Wong, R. J. de Leeuw, N. S. Dosanji, L. R. Kimm, Z. Cheng, D. E. Horsman, C. MacAulay, R. T. Ng, C. J. Brown, E. E. Eichler, and W. L. Lam, "A comprehensive analysis of common copy-number variations in the human genome," *Am. J. Human Genetics*, vol. 80, no. 1, pp. 91–104, 2007.
- [39] V. A. Albert, *Parsimony, Phylogeny, and Genomics*. London, U.K.: Oxford Univ. Press, 2005.
- [40] W. A. Beyer, M. Stein, T. Smith, and S. Ulam, "A molecular sequence metric and evolutionary trees," *Math. Biosci.*, vol. 19, pp. 9–25, 1974.
- [41] M. S. Waterman, T. F. Smith, M. Singh, and W. A. Beyer, "Additive evolutionary trees," *J. Theoretical Biol.*, vol. 64, pp. 199–213, 1977.
- [42] D. Catanzaro, "Estimating phylogenies from molecular data," in *Mathematical Approaches to Polymer Sequence Analysis and Related Problems*, R. Bruni, Ed. New York, NY, USA: Springer, 2011.
- [43] J. Felsenstein, *Inferring Phylogenies*. Sunderland, MA, USA: Sinauer Assoc., 2004.
- [44] N. Bourbaki, *Topological Vector Spaces*. New York, NY, USA: Springer, 2002.
- [45] R. K. Ahuja, T. L. Magnanti, and J. B. Orlin, *Network Flows: Theory, Algorithms, and Applications*. Englewood Cliffs, NJ, USA: Prentice-Hall, 1993.
- [46] R. K. Martin, *Large Scale Linear and Integer Optimization: A Unified Approach*. New York, NY, USA: Springer, 1999.
- [47] D. Hanahan and R. Weinberg, "The hallmarks of cancer," *Cell*, vol. 100, pp. 57–70, 2000.
- [48] D. Hanahan and R. Weinberg, "The hallmarks of cancer: The next generation," *Cell*, vol. 144, pp. 646–674, 2011.
- [49] L. Loeb, "Mutator phenotype may be required for multistage carcinogenesis," *Cancer Res.*, vol. 51, pp. 3075–3079, 1991.
- [50] M. Matsumoto and T. Nishimura, "Mersenne twister: A 623-dimensionally equidistributed uniform pseudo-random number generator," *ACM Trans. Model. Comput. Simul.*, vol. 8, no. 1, pp. 3–30, 1998.



**Daniele Catanzaro** received the PhD degree in operations research from the Free University of Brussels, Belgium, in 2008, for his studies in combinatorial optimization, medical bioinformatics, and molecular phylogenetics. After being a postdoctoral fellow in the Belgian National Fund for Scientific Research (FNRS) and an assistant professor in the Department of Operations, Rijksuniversiteit Groningen, the Netherlands, he joined in 2014 the Louvain School of Management and the Center for Operations Research and Econometrics (CORE) at the Université Catholique de Louvain, where he is currently "Chargé de Cours" (assistant professor) of operations research.



**Stanley E. Shackney** received the MD degree in 1964. He was a senior research investigator and an attending physician in the Medical Oncology Branch at the NIH from 1966 to 1983, and the director at the Laboratory of Cancer Cell Biology and Genetics, Allegheny-Singer Research Institute in Pittsburgh, PA from 1985 to 2008. He later founded the company Intelligent Oncotherapeutics, Inc. He co-authored nearly 100 published papers and made significant contributions to the emerging field of tumor heterogeneity and evolution. He passed away on July 13, 2014.



**Alejandro A. Schäffer** received the BS and MS degrees in applied mathematics from Carnegie Mellon University in 1983. He received the PhD degree in computer science from Stanford University in 1988, focusing on theoretical computer science. In 1992, he switched his research focus to software for genetics. He is best known for leading the development of the genetic linkage analysis package FASTLINK and for doing the implementation of the PSI-BLAST module of the sequence analysis package BLAST. He has also carried out genomic data analysis as one member of large teams doing medical genetics studies, especially studies identifying genes that when mutated cause human primary immunodeficiencies. He is currently a computer scientist at the National Center for Biotechnology Information, National Institutes of Health.



**Russell Schwartz** received the BS, MEng, and PhD degrees from the Department of Electrical Engineering and Computer Science, the Massachusetts of Technology, the last in 2000. He later joined in the Informatics Research group at Celera Genomics. He joined the faculty of Carnegie Mellon University in 2002, where he has pursued a variety of research directions in the field of computational biology, with special interest in computational genetics and computational biophysics. He is currently a professor in Carnegie Mellon's Department of Biological Sciences and Computational Biology Department.

▷ For more information on this or any other computing topic, please visit our Digital Library at [www.computer.org/publications/dlib](http://www.computer.org/publications/dlib).